Making quality
pharmaceuticals
Affordable.

Important Safety Information

PEG-3350 and Electrolytes for Oral Solution is a combination of PEG 3350, an osmotic laxative, and electrolytes indicated for cleansing of the colon in preparation for colonoscopy and barium enema X-ray examination in adults. DOSAGE AND ADMINSTRATION: On day prior to colonoscopy, a light breakfast may be consumed at least 2 hours before starting PEG-3350 and Electrolytes for Oral Solution. Fill the supplied container to the 4-liter fill line and cap. Shake vigorously several times to ensure that the ingredients are dissolved. Drink 8 oz. every 10 minutes until 4 liters are consumed, or rectal effluent is clear. Complete all PEG-3350 and Electrolytes for Oral Solution at least 2 hours before colonoscopy. CONTRAINDICATIONS: Use is contraindicated in the following conditions: gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, hypersensitivity to components of PEG-3350 and Electrolytes for Oral Solution. WARNINGS AND PRECAUTIONS: Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications and consider laboratory assessments prior to and after each use; Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias; Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold; Patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration and consider laboratory testing; Mucosal ulcerations: Consider potential for mucosal ulcerations when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease; Patients at risk for aspiration: Observe during administration; Hypersensitivity reactions including anaphylaxis: Patients should seek medical attention if symptoms occur. ADVERSE REACTIONS: Most common adverse reactions are: nausea, abdominal fullness, bloating, abdominal cramps, vomiting and anal irritation. DRUG INTERACTIONS: Drugs that increase risk of fluid and electrolyte imbalance.
See Full Prescribing Information and Medication Guide.

PEG-3350, Sodium Chloride, Sodium Bicarbonate, and Potassium Chloride for Oral Solution is a combination of PEG 3350, an osmotic laxative, and electrolytes indicated for cleansing of the colon in preparation for colonoscopy in adults and pediatric patients aged 6 months or greater. DOSAGE AND ADMINSTRATION: On day prior to colonoscopy, a light breakfast may be consumed at least 2 hours before starting PEG-3350, Sodium Chloride, Sodium Bicarbonate, and Potassium Chloride for Oral Solution. Fill the supplied container to the 4-liter fill line and cap. Shake vigorously several times to ensure that the ingredients are dissolved. Adults: Drink 8 oz. every 10 minutes until 4 liters are consumed, or rectal effluent is clear. Pediatric patients (aged 6 months or greater): Drink 25 mL/kg/hour orally or administer by NGT. Continue drinking until watery stool is clear and free of solid matter. Complete all PEG-3350, Sodium Chloride, Sodium Bicarbonate, and Potassium Chloride for Oral Solution at least 2 hours before colonoscopy. CONTRAINDICATIONS: Use is contraindicated in the following conditions: gastrointestinal obstruction, ileus or gastric retention, bowel perforation, toxic colitis or toxic megacolon, known allergy or hypersensitivity to components of PEG-3350, Sodium Chloride, Sodium Bicarbonate, and Potassium Chloride for Oral Solution. WARNINGS AND PRECAUTIONS: Risk of fluid and electrolyte abnormalities, arrhythmias, seizures and renal impairment: Assess concurrent medications and consider testing in some patients; Patients with renal insufficiency: Use caution, ensure adequate hydration and consider testing; Suspected GI obstruction or perforation: Rule out the diagnosis before administration; Patients at risk for aspiration: Observe during administration; Not for direct ingestion: Dilute and take with additional water. ADVERSE REACTIONS: Most common adverse reactions are: nausea, abdominal fullness, bloating, abdominal cramps, vomiting and anal irritation. DRUG INTERACTIONS: Drugs that increase risk of fluid and electrolyte imbalance.
See Full Prescribing Information and Medication Guide.

Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 12 years of age and older. CONTRAINDICATIONS: Use is contraindicated in the following conditions: gastrointestinal (GI) obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, hypersensitivity to any ingredients in Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution. DOSAGE AND ADMINISTRATION: Each bottle must be diluted with water to a final volume of 16 ounces (Adults) and 12 ounces (Pediatric patients 12 years of age and older). Must consume additional water after each dose. Stop consumption of all fluids at least 2 hours prior to the colonoscopy. WARNINGS AND PRECAUTIONS: Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after each use; Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk; Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold; Patients with renal impairment or taking medications that affect renal functions: Use caution, ensure adequate hydration and consider laboratory testing; Suspected GI obstruction or perforation: Rule out the diagnosis before administration; Patients at risk for aspiration: Observe during administration. ADVERSE REACTIONS: Most common adverse reactions: Adults: (> 2%) are overall discomfort, abdominal distention, abdominal pain, nausea, and vomiting; Pediatric Patients (>10%) are nausea, abdominal pain, abdominal bloating and vomiting. DRUG INTERACTIONS: Drugs that may increase the risk of fluid and electrolyte abnormalities.
See Full Prescribing Information and Medication Guide.